Distinctive solution conformation of phosphatase inhibitor CPI-17 substituted with aspartate at the phosphorylation-site threohine residue

被引:15
作者
Ohki, SY
Eto, M
Shimizu, M
Takada, R
Brautigan, DL
Kainosho, M
机构
[1] Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA
[2] Tokyo Metropolitan Univ, CREST, Hachioji, Tokyo 1920397, Japan
[3] Tokyo Metropolitan Univ, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan
关键词
CPI-17; NMR structure; phosphorylation-induced conformational change; myosin phosphatase; vascular smooth muscle contraction;
D O I
10.1016/S0022-2836(03)00048-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We present solution NMR structures for wild-type and mutated forms of CPI-17, a phosphoinhibitor for protein phosphatase 1. Phosphorylation of Thr38 of CPI-17 produces a > 1000-fold increase in inhibitory potency for myosin phosphatase. We compared the H-1-N-15 heteronuclear single quantum coherence spectroscopy (HSQC) chemical shifts of wild-type CPI-17, partially phosphorylated CPI-17 and CPI-17 with Thr38 replaced with Asp to introduce a negative charge. There was a switch in the protein conformation due to either Asp substitution or phosphorylation, so we determined the solution NMR structure of the CPI-17 T38D mutant as a model for the active (phospho-) conformation. The structures reveal a molecular switch in conformation that involves the rotation of two of the four helices in the four helix bundle. Despite this conformational switch, there was little increase in the inhibitory potency with T38D. We propose that for this inhibitor, a negative charge at residue 38 is sufficient to trigger an active conformation, but a phosphoryl group is required for full inhibitory potency against protein phosphatase-1. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1539 / 1547
页数:9
相关论文
共 36 条
[1]  
[Anonymous], [No title captured]
[2]   OPTIMIZED RECORDING OF HETERONUCLEAR MULTIDIMENSIONAL NMR-SPECTRA USING PULSED FIELD GRADIENTS [J].
BAX, A ;
POCHAPSKY, SS .
JOURNAL OF MAGNETIC RESONANCE, 1992, 99 (03) :638-643
[3]  
BEULLENS M, 1992, J BIOL CHEM, V267, P16538
[4]   Activation mechanism of the MAP kinase ERK2 by dual phosphorylation [J].
Canagarajah, BJ ;
Khokhlatchev, A ;
Cobb, MH ;
Goldsmith, EJ .
CELL, 1997, 90 (05) :859-869
[5]   NMRPIPE - A MULTIDIMENSIONAL SPECTRAL PROCESSING SYSTEM BASED ON UNIX PIPES [J].
DELAGLIO, F ;
GRZESIEK, S ;
VUISTER, GW ;
ZHU, G ;
PFEIFER, J ;
BAX, A .
JOURNAL OF BIOMOLECULAR NMR, 1995, 6 (03) :277-293
[6]  
DENG JT, 2002, BIOCHEM J, V29, P517
[7]   Structure and ligand of a histone acetyltransferase bromodomain [J].
Dhalluin, C ;
Carlson, JE ;
Zeng, L ;
He, C ;
Aggarwal, AK ;
Zhou, MM .
NATURE, 1999, 399 (6735) :491-496
[8]   A novel phosphoprotein inhibitor of protein type-1 phosphatase holoenzymes [J].
Eto, M ;
Karginov, A ;
Brautigan, DL .
BIOCHEMISTRY, 1999, 38 (51) :16952-16957
[9]   Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: Its specific localization in smooth muscle [J].
Eto, M ;
Senba, S ;
Morita, F ;
Yazawa, M .
FEBS LETTERS, 1997, 410 (2-3) :356-360
[10]   A NOVEL PROTEIN PHOSPHATASE-1 INHIBITORY PROTEIN POTENTIATED BY PROTEIN-KINASE-C - ISOLATION FROM PORCINE AORTA MEDIA AND CHARACTERIZATION [J].
ETO, M ;
OHMORI, T ;
SUZUKI, M ;
FURUYA, K ;
MORITA, F .
JOURNAL OF BIOCHEMISTRY, 1995, 118 (06) :1104-1107